. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: Cancer Causes Control. 2011 Jun 23;22(9):1267–1275. doi: 10.1007/s10552-011-9800-1

Table 3.

Associations between IGF-I and IGFBP-3 levels and malignant melanoma

			Model 1^a	Model 2^b, ^c	Model 3^d

	Cases	Controls	OR_adj (95% CI)	OR_adj (95% CI)	OR_adj (95% CI)
IGF-I (ng/mL)
< 252.0	113	96	1.0	1.0	1.0
252.0 to < 350.6	94	97	0.80 (0.53–1.2)	0.76 (0.49–1.2)	0.66 (0.42–1.1)
≥ 350.6	79	96	0.67 (0.43–1.0)	0.59 (0.37–0.95)	0.44 (0.25–0.79)
P-trend			0.074	0.031	0.0059
Continuous (10 ng/mL increase)			0.99 (0.98–1.0)	0.99 (0.97–1.0)	0.98 (0.96–1.0)
IGFBP-3 (ng/mL)
<4175.8	98	97	1.0	1.0	1.0
4175.8 to < 4987.9	84	96	0.87 (0.58–1.3)	0.83 (0.53–1.3)	0.95 (0.60–1.5)
≥ 4987.9	104	96	1.1 (0.73–1.7)	1.0 (0.64–1.6)	1.3 (0.77–2.2)
P-trend			0.65	0.97	0.31
Continuous (100 ng/mL increase)			1.0 (0.99–1.0)	1.0 (0.99–1.0)	1.0 (1.0–1.0)
IGF-I:IGFBP-3 molar ratio
< 0.2063	103	96	1.00	1.00
0.2063 to <0.2753	102	97	0.97 (0.64–1.5)	1.1 (0.70–1.7)
≥ 0.2753	81	96	0.77 (0.50–1.2)	0.69 (0.43–1.1)
P-trend			0.25	0.14
Continuous (0.010 unit increase)			0.98 (0.95–1.0)	0.97 (0.95–1.0)

Adjusted for age, race, and sex

Additionally adjusted for energy intake, number of lifetime blistering sunburns, height, BMI, ability to tan, education, hair color, and smoking and drinking status.

For Model 2 and 3, one case and one control had missing covariate information.

Model 2 additionally adjusted for IGF-I or IGFBP-3 concentrations (continuous).